State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: A literature review

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 1, 2013, Pages 75-86

  Berardi, Rossana ^a   Caramanti, Miriam ^a   Savini, Agnese ^a   Chiorrini, Silvia ^a   Pierantoni, Chiara ^a   Onofri, Azzurra ^a   Ballatore, Zelmira ^a   De Lisa, Mariagrazia ^a   Mazzanti, Paola ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Anticancer therapy; Cardiotoxicity; Cardiovascular toxicity; Chemotherapy; Targeted therapies

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CAPECITABINE; CARVEDILOL; CYCLOPHOSPHAMIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; DOXORUBICINOL; ENALAPRIL; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; IFOSFAMIDE; LAPATINIB; LOW MOLECULAR WEIGHT HEPARIN; PACLITAXEL; PROSTACYCLIN; SORAFENIB; SUNITINIB; THALIDOMIDE; TRASTUZUMAB; WARFARIN;

ACUTE HEART FAILURE; ANTIANGIOGENIC ACTIVITY; ARTERIAL THROMBOEMBOLISM; BLEEDING; BLOOD PRESSURE MONITOR; BRADYCARDIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOMYOPATHY; CARDIOTOXICITY; CELL PROLIFERATION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; ECG ABNORMALITY; FAINTNESS; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INCIDENCE; LUNG EDEMA; LUNG HEMORRHAGE; MYOCARDITIS; OVERALL SURVIVAL; PERICARDITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROTEINASE INHIBITION; QT PROLONGATION; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ANTICANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR TOXICITY; CHEMOTHERAPY; TARGETED THERAPIES;

ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; NEOPLASMS;

EID: 84884125160     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.02.007     Document Type: Review

References (95)

1. Herbst R.S., Bajorin D.F., Bleiberg H., et al. Clinical cancer advances 2005: major research advances in cancer treatment, prevention, and screening. A report from the American Society of Clinical Oncology. Journal of Clinical Oncology 2006, 24:190-205.
2. Hong R.A., Iimura T., Sumida K.N., Eager R.M. Cardio-oncology/onco-cardiology. Clinical Cardiology 2010, 33(12):733-737.
3. Deng S., Wojnowski L. Genotyping the risk of anthracycline-induced cardiotoxicity. Cardiovascular Toxicology 2007, 7(2):129-134.
4. Mendelsohn M., Karas R. Molecular and cellular basis of cardiovascular gender differences. Science 2005, 308(5728):1583-1587.
5. Raschi E., Vasina V., Ursino M.G., et al. Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacology & Therapeutics 2010, 125(2):196-218.
6. Dolci A., Dominici R., Cardinale D., et al. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. American Journal of Clinical Pathology 2008, 130(5):688-695.
7. Cardinale D. A new frontier: cardio-oncology. Cardiologia 1996, 41(9):887-891.
8. Curigliano G., Mayer E.L., Burstein H.J., Winer E.P., Goldhirsch A. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Progress in Cardiovascular Diseases 2010, 53(2):94-104.
9. Pai V.B., Nahata M.C. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Safety 2000, 22(4):263-302.
10. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97:2869-2879.
11. Van Cutsem E., Hoff P.M., Blum J.L., et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Annals of Oncology 2002, 13:484-485.
12. Schwarzer S., Eber B., Greinix H., et al. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. European Heart Journal 1991, 12:748-750.
13. Durkin W.J., Pugh R.P., Solomon J., et al. Treatment of advanced lymphomas with bleomycin (NSC-125066). Oncology 1976, 33:140-145.
14. Subar M., Muggia F.M. Apparent myocardial ischemia associated with vinblastine administration. Cancer Treatment Reports 1986, 70:690-691.
15. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute 2007, 99:1232-1239.
16. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. New England Journal of Medicine 2007, 356:125-134.
17. Arbuck S.G., Strauss H., Rowinsky E., et al. A reassessment of cardiac toxicity associated with taxol. Journal of the National Cancer Institute Monographs 1993, (15):117-130.
18. Reykdal S., Sham R., Kouides P. Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. Leukemia Research 1995, 19:141-144.
19. Schmidinger M., Zielinski C.C., Vogl U.M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2008, 26(32):5204-5212.
20. Elice F., Jacoub J., Rickles F.R., Falanga A., Rodeghiero F. Hemostatic complications of angiogenesis inhibitors in cancer patients. American Journal of Hematology 2008, 3(11):862-870.
21. Sereno M., Brunello A., Chiappori A., et al. Cardiac toxicity: old and new issues in anti-cancer drugs. Clinical and Translational Oncology 2008, 10(1):35-46.
22. Svoboda M., Poprach A., Dobes S., Kiss I., Vyzula R. Cardiac toxicity of targeted therapies used in the treatment for solid tumors: a review. Cardiovascular Toxicology 2012, 12:191-207.
23. Harbeck N., Ewer M.S., De Laurentiis M., Suter T.M., Ewer S.M. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Annals of Oncology 2011, 22:1250-1258.
24. Sawyer D.B., Zuppinger C., Miller T.A., Eppenberger H.M., Suter T.M. Modulation of anthracycline-induced myofi brillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 2002, 105(13):1551-1554.
25. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Seminars in Oncology 2006, 33(3 Suppl. 8):S2-S7.
26. Ewer M.S., Lippman S.M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. Journal of Clinical Oncology 2005, 23:2900-2902.
27. Wouters K.A., Kremer L.C., Miller T.L., Herman E.H., Lipshultz S.E. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. British Journal of Haematology 2005, 131:561-578.
28. Lyu Y.L., Kerrigan J.E., Lin C.P., et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Research 2007, 67:8839-8846.
29. Crone S.A., Zhao Y.Y., Fan L., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Medicine 2002, 8(5):459-465.
30. Feldman A.M., Lorell B.H., Reis S.E. Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 2000, 102(3):272-274.
31. Perez E.A., Koehler M., Byrne J., Preston A.J., Rappold E., Ewer M.S. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clinic Proceedings 2008, 83(6):679-686.
32. Alter P., Herzum M., Soufi M., Schaefer J.R., Maisch B. Cardiotoxicity of 5-fluorouracil. Cardiovascular & Hematological Agents in Medicinal Chemistry 2006, 4(1):1-5.
33. Yeh E.T., Bickford C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. Journal of the American College of Cardiology 2009, 53(24):2231-2247.
34. Van Heeckeren W.J., Sanborn S.L., Narayan A., et al. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Current Opinion in Hematology 2007, 14(5):468-480.
35. Albini A., Noonan D.M. Rescuing COX-2 inhibitors from the waste bin. Journal of the National Cancer Institute 2005, 97(11):859-860.
36. Czaykowski P.M., Moore M.J., Tannock I.F. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. Journal of Urology 1998, 160(6):2021-2024.
37. Fainaru O., Adini I., Benny O., et al. Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability. FASEB Journal 2008, 22(10):3728-3735.
38. Jain M., Townsend R.R. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Current Hypertension Reports 2007, 9(4):320-328.
39. Watson G., Kugel M., Shih H., Tak Piech C., McKenzie R. Cardiac comorbidities in women with metastatic breast cancer treated with doxorubicin-based and non-doxorubicin-based chemotherapy. Journal of Clinical Oncology 2009, 27(15S):1052.
40. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. British Journal of Cancer 2007, 96(12):1788-1795.
41. Dincer M., Altundag K. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Annals of Pharmacotherapy 2006, 40(12):2278-2279.
42. Lainscak M., Dagres N., Filippatos G.S., Anker S.D., Kremastinos D.T. Atrial fibrillation in chronic non-cardiac disease: where do we stand?. International Journal of Cardiology 2008, 128(3):311-315.
43. Van der Hooft C.S., Heeringa J., van Herpen G., Kors J.A., Kingma J.H., Stricker B.H. Drug-induced atrial fibrillation. Journal of the American College of Cardiology 2004, 44(11):2117-2124.
44. Guzzetti S., Costantino G., Fundaro C. Systemic inflammation, atrial fibrillation, and cancer. Circulation 2002, 106(9):e40. author reply e40.
45. Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine 1979, 91:710-717.
46. Grenier M.A., Lipshultz S.E. Epidemiology of anthracycline cardiotoxicity in children and adults. Seminars in Oncology 1998, 25:72-85.
47. Lipshultz S.E., Alvarez J.A., Scully R.E. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008, 94:525-533.
48. Broder H., Gottlieb R., Lepor N. Chemotherapy and cardiotoxicity. Reviews in Cardiovascular Medicine 2008, 9(2):75-83.
49. Pai V.B., Nahata M.C. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Safety 2000, 22:263-302.
50. Gharib M.I., Burnett A.K. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. European Journal of Heart Failure 2002, 4:235-242.
51. Arbuck S.G., Strauss H., Rowinsky E., Christian M., Suffness M., Adams J., et al. A reassessment of cardiac toxicity associated with taxol. Journal of the National Cancer Institute Monographs 1993, 117-130.
52. Salvatorelli E., Menna P., Cascegna S., Liberi G., Calafiore A.M., Gianni L., et al. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. Journal of Pharmacology and Experimental Therapeutics 2006, 318:424-433.
53. De Forni M., Malet-Martino M.C., Jaillais P., Shubinski R.E., Bachaud J.M., Lemaire L., et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. Journal of Clinical Oncology 1992, 10:1795-1801.
54. Collins C., Weiden P.L. Cardiotoxicity of 5-fluorouracil. Cancer Treatment Reports 1987, 71:733-736.
55. Jensen S.A., Sorensen J.B. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemotherapy and Pharmacology 2006, 58:487-493.
56. Gottdiener J.S., Appelbaum F.R., Ferrans V.J., Deisseroth A., Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Archives of Internal Medicine 1981, 141:758-763.
57. Taniguchi I. Clinical significance of cyclophosphamide-induced cardiotoxicity. Journal of Internal Medicine 2005, 44:89-90.
58. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. Journal of Clinical Oncology 2005, 23:792-799.
59. Vaklavas C., Lenihan D., Kurzrock R., Tsimberidou A.M. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?. Oncologist 2010, 15:130-141.
60. Scartozzi M., Galizia E., Chiorrini S., et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Annals of Oncology 2009, 20(2):227-230.
61. Kabbinavar F.F., Schulz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. Journal of Clinical Oncology 2005, 23:3697-3705.
62. Sane D.C., Anton L., Brosnihan K.B. Angiogenic growth factors and hypertension. Angiogenesis 2004, 7:193-201.
63. Veronese M.L., Mosenkis A., Flaherty K.T., et al. Mechanisms of hypertension associated with BAY 43-9006. Journal of Clinical Oncology 2006, 24:1363-1369.
64. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003, 42:1206-1252.
65. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. Journal of Clinical Oncology 2002, 20:1215-1221.
66. Suter T.M., Procter M., van Veldhuisen D.J., Muscholl M., Bergh J., Carlomagno C., et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. Journal of Clinical Oncology 2007, 25:3859-3865.
67. Crone S.A., Zhao Y.Y., Fan L., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Medicine 2002, 8:459-465.
68. Guglin M., Cutro R., Mishkin J.D. Trastuzumab-induced cardiomyopathy. Journal of Cardiac Failure 2008, 14:437-444.
69. Orphanos G.S., Ioannidis G.N., Ardavanis A.G. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncologica 2009, 48:964-970.
70. Perez E.A., Koehler M., Byrne J., Preston A.J., Rappold E., Ewer M.S. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clinic Proceedings 2008, 83:679-686.
71. Shiojima I., Sato K., Izumiya Y., Schiekofer S., Ito M., Liao R., et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. Journal of Clinical Investigation 2005, 115:2108-2118.
72. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nature Reviews Drug Discovery 2007, 6:734-745.
73. Chu T.F., Rupnick M.A., Kerkela R., Dallabrida S.M., Zurakowski D., Nguyen L., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370:2011-2019.
74. Motzer R.J., Hutson T.E., Tomczak P., Michaelson, Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine 2007, 356:115-124.
75. Khakoo A.Y., Kassiotis C.M., Tannir N., et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008, 112:2500-2508.
76. Force T., Krause D.S., Van Etten R.A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews Cancer 2007, 7(5):332-344.
77. Kerkela R., Woulfe K.C., Durand J.B., et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clinical and Translational Science 2009, 2:15-25.
78. Popat S., Smith I.E. Therapy insight: anthracyclines and trastuzumab-the optimal management of cardiotoxic side effects. Nature Clinical Practice Oncology 2008, 5(6):324-335.
79. Tassan-Mangina S., Codorean D., Metivier M., et al. Tissue Doppler imaging and conventional echocardiography after antracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. European Journal of Echocardiography 2006, 7:141-146.
80. Shan K., Lincoff A.M., Young J.B. Anthracycline-induced cardiotoxicity. Annals of Internal Medicine 1996, 125:47-58.
81. Ewer M.S., Lenihan D.J. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?. Journal of Clinical Oncology 2008, 26:1201-1203.
82. Bovelli D., Plataniotis G., Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO clinical practice guidelines. Annals of Oncology 2010, 21:277-282.
83. Cardinale D., Sandri M.T., Martinoni A., et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Annals of Oncology 2002, 13:710-715.
84. Nousiainen T., Vanninen E., Jantunen E., et al. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. Journal of Internal Medicine 2002, 251:228-234.
85. Sandri M.T., Salvatici M., Cardinale D., et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?. Clinical Chemistry 2005, 51(8):1405-1410.
86. Cardinale D., Colombo A., Sandri M.T., et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006, 114:2474-2481.
87. Hunt S.A. American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Journal of the American College of Cardiology 2005, 46. e1-82.
88. Jones A.L., Barlow M., Barrett-Lee P.J., Canney P.A., Gilmour I.M., Robb S.D., et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. British Journal of Cancer 2009, 100:684-692.
89. Kalay N., Basar E., Ozdogru I., et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. Journal of the American College of Cardiology 2006, 48:2258-2262.
90. Meinardi M.T., van Veldhuisen D.J., Gietema J.A., et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. Journal of Clinical Oncology 2001, 19:2746-2753.
91. http://www.fda.gov/Drugs/DrugSafety/ucm263729.htm.
92. Ederhy S., Izzedine H., Massard C., et al. Cardiac side effects of molecular targeted therapies: toward a better dialogue between oncologists and cardiologists. Critical Reviews in Oncology/Hematology 2011, 80:369-379.
93. Cardinale D., Colombo A., Lamantia G., Colombo N., Civelli M., De Giacomi G., et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology 2010, 55:213-220.
94. Tallaj J.A., Franco V., Rayburn B.K., et al. Response of doxorubicineinduced cardiomyopathy to the current management strategy of heartfailure. J Heart Lung Transplant 2005, 24:2196-2201.
95. Kearon C., Kahn S.R., Agnelli G., et al. Antithrombothic therapy forvenous thromboembolic disease: American College of Chest Physiciansevidence-based clinical practice guidelines (8th edition). Chest 2008, 133:454S-545S.